[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334978-105":59,"doc-detail-334978-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","whole-brain-radiation-therapy-plus-simultaneous-integrated-boost-for-brain-metastases-from-breast-cancers-research-findings","Whole-brain radiation therapy plus simultaneous integrated boost for brain metastases from breast cancers - research findings","","Whole-brain radiation therapy combined with simultaneous integrated boost (WBRT+SIB) for breast-cancer brain metastases lacks clear evidence on clinical efficacy. A single-center retrospective study evaluated consecutive patients receiving hypofractionated IMRT-SIB, analyzing response, survival, prognostic factors, and patterns of failure. Among 27 eligible patients, 14.8% achieved clinical complete response and 51.9% partial response. Median brain progression-free survival was 8.60 months and median overall survival 16.8 months, with failures occurring in- and out-of-field. Results support improved tumor control and clinical outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/whole-brain-radiation-therapy-plus-simultaneous-integrated-boost-for-brain-metastases-from-breast-cancers-research-findings/334978/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/whole-brain-radiation-therapy-plus-simultaneous-integrated-boost-for-brain-metastases-from-breast-cancers-research-findings/334978.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment strategy does the study evaluate for breast cancer brain metastases?","Question",{"text":112,"@type":113},"The study evaluates whole-brain radiation therapy (WBRT) combined with a simultaneous integrated boost (SIB) delivered using an IMRT-based hypofractionated approach.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were clinical outcomes assessed in this retrospective study?",{"text":117,"@type":113},"Clinical outcomes included response rates of brain lesions, brain progression-free survival, overall survival, and patterns of treatment failure.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main response and survival results?",{"text":121,"@type":113},"Among 27 patients, 14.8% achieved clinical complete response and 51.9% had partial response. Median brain progression-free survival was 8.60 months and median overall survival was 16.8 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334978,1790186573,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Submitted 14 November 2023 Accepted 14 June 2024  \nPublished 12 July 2024  \nCorresponding authors Qiuji Wu, [wuqiuji@126.com](wuqiuji@126.com)[ ](wuqiuji@126.com)Yahua Zhong, [doctorzyh73@163.com](doctorzyh73@163.com)  \nAcademic editor Sonia Oliveira  \nAdditional Information and Declarations can be found on page 12  \nDOI 10.7717/peerj.17696  \n Copyright 2024 Zhang et al.  \nDistributed under  \nCreative Commons CC-BY 4.0  \nWhole-brain radiation therapy plus simultaneous integrated boost for brain metastases from breast cancers  \nHongyan Zhang*, Qiuji Wu *, Li Li, Linwei Wang and Yahua Zhong Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University,  \nWuhan, Hubei Province, China  \n* These authors contributed equally to this work.  \nABSTRACT  \nBackground: The effect of whole-brain radiation therapy (WBRT) plus simultaneous integrated boost (SIB) in brain metastasis from breast cancers has not been demonstrated.  \nMethod: In this single-center retrospective study, we reviewed consecutive breast cancer patients who developed brain metastasis and were treated with hypofractionated radiation therapy plus WBRT using intensity-modulated radiation therapy (IMRT)-SIB approaches. We analyzed clinical outcomes, prognostic factors and patterns of treatment failure.  \nResult: A total of 27 patients were eligible for analysis. Four (14.8%) patients achieved clinical complete response and 14 (51.9%) had partial response of brain lesions. The other nine patients were not evaluated for brain tumor response. The median brain progression-free survival was 8.60 (95% CI [6.43–13.33]) months and the median overall survival was 16.8 (95% CI [13.3–27.7]) months. Three patients had in-ﬁeld failure, ﬁve had out-ﬁeld failure and two had in-ﬁeld and out-ﬁeld failure. Conclusion: WBRT plus SIB led to improved tumor control and clinical outcome in breast cancer patients with brain metastasis.  \nSubjects Oncology, Women’s Health, Palliative Care  \nKeywords Breast cancer, Brain metastasis, WBRT, Simultaneous integrated boost, Outcome INTRODUCTION  \nBreast cancer is the leading malignancy in women worldwide. It is estimated that 281,550 new cases of female breast cancers in United States, leading to around 43,600 death in 2021 (Siegel et al., 2021) . In China, these numbers were 268,600 new cases and 69,500 deaths in 2015 (Chen et al., 2016) . Breast cancer is a common causal disease of cancer brain metastasis. Up to 5.1% of all breast cancers would develop brain metastasis (BM) and 14.2% of metastatic breast cancer were presented with BM (Barnholtz-Sloan et al., 2004) . BM is a signiﬁcantly poor prognostic factor in breast cancer patients, with the median overall survival being only around four months (Castaneda et al., 2015) . Associated poor prognostic factors include advanced stage, higher grade, estrogen receptor (ER) negativity, shorter time to develop BM and >3 brain lesions (Castaneda et al., 2015) . Since the incidence of BM is increasing, it represents a critical problem that is not only  \nHow to cite this article Zhang H, Wu Q, Li L, Wang L, Zhong Y. 2024. Whole-brain radiation therapy plus simultaneous integrated boost for brain metastases from breast cancers. PeerJ 12:e17696 DOI 10.7717/peerj.17696  \nlife-threatening to breast cancer patients but also signiﬁcantly increase the cost of medical care (Pelletier et al., 2008) .  \nTreatments of BM from breast cancers have evolved with the progression of radiotherapy techniques, and the development of novel chemotherapeutic and targeted drugs. Surgery is often ﬁrstly recommended whenever eligible. Stereotactic radiosurgery (SRS) shows similar tumor control effect but reduces brain irradiation. Whole brain radiotherapy (WBRT) is now increasingly challenged given signiﬁcant cognitive impairment, especially for those long-survived patients following targeted therapies (Chargari et al., 2010) . W","cbCaicuhYirmxs6g","https://ap.wps.com/l/cbCaicuhYirmxs6g","pdf",5554566,15,"English","# Abstract\n# Introduction\n## Background and rationale\n## Limitations of existing treatments\n# Materials and Methods\n## Patient cohort\n## Inclusion criteria","[{\"question\":\"What treatment strategy does the study evaluate for breast cancer brain metastases?\",\"answer\":\"The study evaluates whole-brain radiation therapy (WBRT) combined with a simultaneous integrated boost (SIB) delivered using an IMRT-based hypofractionated approach.\"},{\"question\":\"How were clinical outcomes assessed in this retrospective study?\",\"answer\":\"Clinical outcomes included response rates of brain lesions, brain progression-free survival, overall survival, and patterns of treatment failure.\"},{\"question\":\"What were the main response and survival results?\",\"answer\":\"Among 27 patients, 14.8% achieved clinical complete response and 51.9% had partial response. Median brain progression-free survival was 8.60 months and median overall survival was 16.8 months.\"}]","Whole-brain radiation therapy plus simultaneous integrated boost for brain metastases from breast cancers - research findings | PDF",1790009112,38]